相关实验视频
Updated: Sep 10, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
糖尿病治疗中的对话干预措施:系统性审查
Moshe Shegal1, Lin Tao Hu2, Erik Friesen2
1Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.
Diabetes research and clinical practice
|August 21, 2025
概括
谈话药物对糖尿病自我管理有前途,改善血糖控制和健康行为. 需要进一步的研究来证实它们在不同人群中的安全性和有效性.
科学领域:
- 数字卫生干预措施
- 医疗保健中的人工智能
- 糖尿病管理
背景情况:
- 会话代理 (CA) 是人工智能驱动的模拟人类对话的工具.
- 在慢性病的自我管理中提供潜在的支持.
- 糖尿病护理是一个越来越多地探索CA的领域.
研究的目的:
- 系统地审查CA在糖尿病治疗中的有效性,可接受性和安全性.
- 综合符合条件的关于在糖尿病治疗中使用CA的研究证据.
- 鉴定糖尿病的研究缺口和未来的CA实施方向.
主要方法:
- 对13个国家的9076名参与者进行的16项研究进行了系统审查.
- 搜索了六个电子数据库从创立到2024年6月.
- 包括的研究在设计,人群,糖尿病类型和干预持续时间方面有所不同.
主要成果:
- 大多数研究报告了血糖控制 (HbA1c 0.3% - 1.0%) 的改善,药物坚持和健康行为.
- 用户的接受度总体上是积极的,有些人对交互质量感到不满.
- 安全性数据有限,临床升级方案的应用不一致.
结论:
- 对话型药物显示出可扩展,以患者为中心的糖尿病治疗工具的潜力.
- 需要高质量的研究来验证对不同患者群体的临床影响,安全性和适用性.
- 需要进一步研究最佳的CA设计和实施策略.
相关概念视频
Diabetes: Management and Pharmacotherapy
362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Diabetes: Symptoms, Diagnosis, and Complications
687
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
687
SBAR II: Application of SBAR
4.7K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.7K
Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257

